Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne
- PMID: 25796182
- DOI: 10.1001/jamadermatol.2015.34
Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne
Abstract
Importance: Spironolactone has been shown to be an effective treatment option for hormonally mediated acne but can cause hyperkalemia. The prevalence of hyperkalemia among healthy young women taking spironolactone for acne is unclear.
Objective: To measure the rate of hyperkalemia in healthy young women taking spironolactone for acne or for an endocrine disorder with associated acne.
Design, setting, and participants: Retrospective study of healthy young women taking spironolactone for acne. Data from December 1, 2000, through March 31, 2014, were obtained from a clinical data repository. Outpatient data were collected from 2 tertiary care centers in the United States. We analyzed rates of hyperkalemia in 974 healthy young women taking spironolactone for acne. We also analyzed 1165 healthy young women taking and not taking spironolactone to obtain a profile for the baseline rate of hyperkalemia in this population. Exclusion criteria were cardiovascular disease, renal failure, and the use of medications that affect the renin-angiotensin-aldosterone system.
Main outcomes and measures: The rate of hyperkalemia in healthy young women taking spironolactone for acne was calculated. Secondary measures included spironolactone prescriber profiles and potassium monitoring practices.
Results: There were 13 abnormal serum potassium measurements in 1802 measurements obtained among young women receiving spironolactone therapy, yielding a hyperkalemia rate of 0.72%, equivalent to the 0.76% baseline rate of hyperkalemia in this population. Repeat testing in 6 of 13 patients demonstrated normal values, suggesting that these measurements may have been erroneous. In the remaining 7 patients, no action was taken.
Conclusions and relevance: The rate of hyperkalemia in healthy young women taking spironolactone for acne is equivalent to the baseline rate of hyperkalemia in this population. Routine potassium monitoring is unnecessary for healthy women taking spironolactone for acne.
Comment in
-
K+larity for Spironolactone: At Last!JAMA Dermatol. 2015 Sep;151(9):926-7. doi: 10.1001/jamadermatol.2015.35. JAMA Dermatol. 2015. PMID: 25796224 No abstract available.
Similar articles
-
Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.J Med Assoc Thai. 2013 Aug;96(8):905-10. J Med Assoc Thai. 2013. PMID: 23991595
-
Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study.Dermatology. 2017;233(2-3):141-144. doi: 10.1159/000471799. Epub 2017 May 5. Dermatology. 2017. PMID: 28472793
-
Temporal Trends and Clinician Variability in Potassium Monitoring of Healthy Young Women Treated for Acne With Spironolactone.JAMA Dermatol. 2021 Mar 1;157(3):296-300. doi: 10.1001/jamadermatol.2020.5468. JAMA Dermatol. 2021. PMID: 33502462 Free PMC article.
-
Spironolactone in dermatology: uses in acne and beyond.Clin Exp Dermatol. 2020 Dec;45(8):986-993. doi: 10.1111/ced.14340. Epub 2020 Aug 26. Clin Exp Dermatol. 2020. PMID: 32844462 Review.
-
Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.Ann Pharmacother. 2016 Jun;50(6):502-10. doi: 10.1177/1060028016640794. Epub 2016 Mar 23. Ann Pharmacother. 2016. PMID: 27009290 Review.
Cited by
-
A Prospective Randomized Trial Comparing Quality of Life in Adult Female Acne Treated with Azelaic Acid 15% Gel versus Oral Spironolactone.Clin Cosmet Investig Dermatol. 2024 Oct 21;17:2335-2343. doi: 10.2147/CCID.S463295. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39444646 Free PMC article.
-
What's New After NICE Acne Guidelines.Dermatol Ther (Heidelb). 2024 Oct;14(10):2727-2738. doi: 10.1007/s13555-024-01275-0. Epub 2024 Sep 21. Dermatol Ther (Heidelb). 2024. PMID: 39305432 Free PMC article. Review.
-
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT.Health Technol Assess. 2024 Sep;28(56):1-86. doi: 10.3310/MYJT6804. Health Technol Assess. 2024. PMID: 39268864 Free PMC article. Clinical Trial.
-
Acne treatment: research progress and new perspectives.Front Med (Lausanne). 2024 Jul 10;11:1425675. doi: 10.3389/fmed.2024.1425675. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39050538 Free PMC article. Review.
-
The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis.PLoS One. 2024 May 30;19(5):e0298155. doi: 10.1371/journal.pone.0298155. eCollection 2024. PLoS One. 2024. PMID: 38814916 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
